American Century Companies Inc. decreased its position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 41.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 65,146 shares of the company's stock after selling 45,302 shares during the quarter. American Century Companies Inc. owned approximately 0.06% of Tango Therapeutics worth $89,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Stonebrook Private Inc. acquired a new position in shares of Tango Therapeutics in the 4th quarter valued at $34,000. Ameriprise Financial Inc. acquired a new position in shares of Tango Therapeutics in the 4th quarter valued at $35,000. Sherbrooke Park Advisers LLC acquired a new position in shares of Tango Therapeutics in the 4th quarter valued at $38,000. Squarepoint Ops LLC acquired a new position in shares of Tango Therapeutics in the 4th quarter valued at $40,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Tango Therapeutics by 29.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,998 shares of the company's stock valued at $65,000 after purchasing an additional 4,813 shares during the period. Institutional investors and hedge funds own 78.99% of the company's stock.
Tango Therapeutics Stock Performance
Shares of NASDAQ TNGX traded down $0.31 during midday trading on Friday, reaching $6.53. The company's stock had a trading volume of 1,780,986 shares, compared to its average volume of 1,338,086. Tango Therapeutics, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $10.85. The business's 50 day moving average price is $6.60 and its two-hundred day moving average price is $3.87. The company has a market cap of $726.53 million, a P/E ratio of -4.91 and a beta of 1.64.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.35) EPS for the quarter, meeting the consensus estimate of ($0.35). The business had revenue of $3.18 million during the quarter, compared to the consensus estimate of $6.41 million. Tango Therapeutics had a negative net margin of 599.11% and a negative return on equity of 79.72%. Sell-side analysts forecast that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.
Insider Buying and Selling at Tango Therapeutics
In related news, major shareholder Rock Ventures Iv L.P. Third sold 86,459 shares of the business's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $7.04, for a total value of $608,671.36. Following the transaction, the insider owned 14,727,516 shares in the company, valued at $103,681,712.64. The trade was a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 2,131,559 shares of company stock valued at $14,935,371 over the last quarter. Insiders own 7.50% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts recently commented on TNGX shares. Piper Sandler started coverage on shares of Tango Therapeutics in a research report on Monday, August 18th. They issued an "overweight" rating and a $11.00 price objective for the company. Guggenheim upped their price objective on shares of Tango Therapeutics from $8.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Tango Therapeutics presently has a consensus rating of "Buy" and an average target price of $10.50.
View Our Latest Research Report on TNGX
Tango Therapeutics Company Profile
(
Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Further Reading
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
